Continuous low-dose (metronomic) chemotherapy on rat prostate tumors evaluated using MRI in vivo and comparison with histology
about
Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserineA review of the past, present, and future directions of neoplasiaNeoplasia: Where We Have Been and Where We Are GoingPhase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.Can DCEMRI assess the effect of green tea on the angiogenic properties of rodent prostate tumors?Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessmentMetabolism and transport of oxazaphosphorines and the clinical implications.Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer.Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy?In vivo small animal imaging: current status and future prospects.MRI & MRS assessment of the role of the tumour microenvironment in response to therapy.Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments.A role for dynamic contrast-enhanced magnetic resonance imaging in predicting tumour radiation response.Metastasizing, Luciferase Transduced MAT‑Lu Rat Prostate Cancer Models: Follow up of Bolus and Metronomic Therapy with Doxorubicin as Model Drug.Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers.Neoplasia: An Anniversary of Progress.
P2860
Q24605725-B795E893-312E-4AAB-8663-1B04DCEC5552Q28389391-E08FA42B-2910-4E5D-B320-54E678E3AC06Q28395095-31BA971F-4425-4D69-B7FD-219F89371972Q33388306-F7F69675-2828-407C-BBA2-7A4BB9CEDEBCQ33489265-EC0DB2A7-E0E8-4E1A-8135-512952B1459BQ34497992-AE8BA49A-C3C0-4767-BC33-B2B5780172F5Q34765364-500D478E-FCD9-4B4C-87A4-37BF369E038DQ36360811-4140934B-D8EB-479E-9511-D7B6B5AA8163Q36866123-1CFAC216-6F96-4110-9458-A3CB04647084Q37310699-4236CC77-8909-4F34-AA41-2F5A26E373DEQ37837837-48BDC2D8-CE8D-436F-973F-1B01A38F8DD7Q37875004-2411E308-666B-4D07-976F-421D07F5A676Q38168371-BAC332D7-6FBA-4B53-B761-0CECED1FB410Q39799440-9E764054-D46B-4142-B286-DDC4FF0673AAQ42576985-7273A463-D6E5-4938-85B7-51803D8E8013Q43410555-3DE0F898-BD02-438A-B807-6A6BCA5676F8Q46932476-C8626588-08CD-4FEF-BC37-C800FAE0E8E5
P2860
Continuous low-dose (metronomic) chemotherapy on rat prostate tumors evaluated using MRI in vivo and comparison with histology
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Continuous low-dose (metronomi ...... and comparison with histology
@ast
Continuous low-dose (metronomi ...... and comparison with histology
@en
Continuous low-dose
@nl
type
label
Continuous low-dose (metronomi ...... and comparison with histology
@ast
Continuous low-dose (metronomi ...... and comparison with histology
@en
Continuous low-dose
@nl
prefLabel
Continuous low-dose (metronomi ...... and comparison with histology
@ast
Continuous low-dose (metronomi ...... and comparison with histology
@en
Continuous low-dose
@nl
P2093
P2860
P356
P1433
P1476
Continuous low-dose (metronomi ...... and comparison with histology
@en
P2093
Dawen Zhao
Eric W Hahn
P2860
P304
P356
10.1593/NEO.04757
P50
P577
2005-07-01T00:00:00Z